ClinicalTrials.gg
CompletedNCT00442845ACTFASTUpdated Feb 18, 2021

Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)

A Phase 4 interventional study of Atorvastatin (Lipitor) in Coronary Arteriosclerosis, Diabetes Mellitus, Type 2 and Cerebrovascular Accident, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 121 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,080
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 33 studies testing atorvastatin in Coronary Artery Disease — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Coronary Artery Disease.

Enrollment
Largest of 33
2,080 · median 120
Started
2003
with 4 others
Phase 4
19 of 33
1 open now
Registered
6th of 33
by date
Lead sponsor
3 of 33
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 33 studies testing atorvastatin in Coronary Artery Disease, this one has the largest enrollment, is one of 5 that started in 2003, is one of 19 in phase 4, and was the 6th registered.

Coronary Artery Disease

4,865 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 33 studies testing atorvastatin in Coronary Artery Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing atorvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)

03

Conditions studied

  • Coronary Arteriosclerosis
  • Diabetes Mellitus, Type 2
  • Cerebrovascular Accident
  • Dyslipidemia
  • Peripheral Vascular Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • High cholesterol blood levels (LDL-cholesterol above 100 mg/dL up to 220 mg/dL.
  • Triglycerides up to 600 mg/dL.
  • History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation, use of high statin doses (>40mg) at baseline, liver or renal problems, use of other drugs that would interfere with evaluation of efficacy or cause safety problems, uncontrolled hypertension, diabetes or hypothyroidism, recent cardiac event of procedure, high baseline CPK levels
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,080 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.

Secondary outcomes

  1. Percentage of subjects achieving:

  2. LDL-C target <100 mg/dL (<2.6 mmol/L) after 6 weeks of treatment.

  3. Total cholesterol (TC)/HDL-C ratio target (<4.0) after 6 and 12 weeks of treatment.

  4. Either the LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.

  5. Both the LDL-C <100mg/dL (<2.6 mmol/L) and TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.

  6. LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment by LDL-C strata.

  7. LDL-C target (<100 mg/dL) by primary inclusion diagnosis (CHD, CHD-equivalent, diabetes or 10-year CHD risk-equivalent >20%).

  8. The mean percent change in LDL-C, high density lipoprotein cholesterol (HDL-C),TC/HDL-C ratio, non HDL-C (in subjects with triglycerides [TG] ≥200 mg/dL or 2.3 mmol/L), TC and TG from baseline to 6 and 12 weeks of treatment.

  9. Change from baseline in apolipoprotein-B (Apo-B) and change from baseline in glycosylated hemoglobin (HbA1c) was assessed at 12 weeks.

07

Study locations

121 sites
  • Pfizer Investigational Site
    Mississauga, Ontario, Cameroon
  • Pfizer Investigational Site
    Calgary, Alberta, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta, Canada
  • Pfizer Investigational Site
    Medicine Hat, Alberta, Canada
  • Pfizer Investigational Site
    Red Deer, Alberta, Canada
  • Pfizer Investigational Site
    Campbell River, British Columbia, Canada
  • Pfizer Investigational Site
    Maple Ridge, British Columbia, Canada
  • Pfizer Investigational Site
    Nanaimo, British Columbia, Canada
  • Pfizer Investigational Site
    New Westminster, British Columbia, Canada
  • Pfizer Investigational Site
    Richmond, British Columbia, Canada
  • Pfizer Investigational Site
    Surrey, British Columbia, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia, Canada
  • Pfizer Investigational Site
    Vernon, British Columbia, Canada
  • Pfizer Investigational Site
    Victoria, British Columbia, Canada
  • Pfizer Investigational Site
    Brandon, Manitoba, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba, Canada
  • Pfizer Investigational Site
    Ajax, Ontario, Canada
  • Pfizer Investigational Site
    Brampton, Ontario, Canada
  • Pfizer Investigational Site
    Burlington, Ontario, Canada
  • Pfizer Investigational Site
    Cambridge, Ontario, Canada
  • Pfizer Investigational Site
    Cornwall, Ontario, Canada
  • Pfizer Investigational Site
    Etobicoke, Ontario, Canada
  • Pfizer Investigational Site
    Mississauga, Ontario, Canada
  • Pfizer Investigational Site
    Niagara Falls, Ontario, Canada
  • Pfizer Investigational Site
    North York, Ontario, Canada
  • Pfizer Investigational Site
    Orillia, Ontario, Canada
  • Pfizer Investigational Site
    Oshawa, Ontario, Canada
  • Pfizer Investigational Site
    Rexdale, Ontario, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario, Canada
  • Pfizer Investigational Site
    Scarborough, Ontario, Canada
  • Pfizer Investigational Site
    Simcoe, Ontario, Canada
  • Pfizer Investigational Site
    Thunder Bay, Ontario, Canada
  • Pfizer Investigational Site
    Toronto, Ontario, Canada
  • Pfizer Investigational Site
    Weston, Ontario, Canada
  • Pfizer Investigational Site
    Whitby, Ontario, Canada
  • Pfizer Investigational Site
    Willowdale, Ontario, Canada
  • Pfizer Investigational Site
    Chicoutimi, Quebec, Canada
  • Pfizer Investigational Site
    Cowansville, Quebec, Canada
  • Pfizer Investigational Site
    Drummondville, Quebec, Canada
  • Pfizer Investigational Site
    Joliette, Quebec, Canada
  • Pfizer Investigational Site
    Laval, Quebec, Canada
  • Pfizer Investigational Site
    Levis, Quebec, Canada
  • Pfizer Investigational Site
    Maria, Quebec, Canada
  • Pfizer Investigational Site
    Montreal, Quebec, Canada
  • Pfizer Investigational Site
    Newport, Quebec, Canada
  • Pfizer Investigational Site
    Pointe Claire, Quebec, Canada
  • Pfizer Investigational Site
    Repentigny, Quebec, Canada
  • Pfizer Investigational Site
    Saint Hyacinthe, Quebec, Canada
  • Pfizer Investigational Site
    Sainte Foy, Quebec, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec, Canada
  • Pfizer Investigational Site
    St-georges (beauce), Quebec, Canada
  • Pfizer Investigational Site
    St. Lambert, Quebec, Canada
  • Pfizer Investigational Site
    Thetford Mines, Quebec, Canada
  • Pfizer Investigational Site
    Vaudreuil, Quebec, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan, Canada
  • Pfizer Investigational Site
    Quebec, Canada
  • Pfizer Investigational Site
    Tricase, (le), Italy
  • Pfizer Investigational Site
    Vimercate, (mi), Italy
  • Pfizer Investigational Site
    Somma Lombardo, (va), Italy
  • Pfizer Investigational Site
    Asti, Italy
  • Pfizer Investigational Site
    Bari, Italy
  • Pfizer Investigational Site
    Belluno, Italy
  • Pfizer Investigational Site
    Bologna, Italy
  • Pfizer Investigational Site
    Bolzano, Italy
  • Pfizer Investigational Site
    Catania, Italy
  • Pfizer Investigational Site
    Chieti, Italy
  • Pfizer Investigational Site
    Ferrara, Italy
  • Pfizer Investigational Site
    Firenze, Italy
  • Pfizer Investigational Site
    Foggia, Italy
  • Pfizer Investigational Site
    Grosseto, Italy
  • Pfizer Investigational Site
    Napoli, Italy
  • Pfizer Investigational Site
    Novara, Italy
  • Pfizer Investigational Site
    Palermo, Italy
  • Pfizer Investigational Site
    Perugia, Italy
  • Pfizer Investigational Site
    Potenza, Italy
  • Pfizer Investigational Site
    Prato, Italy
  • Pfizer Investigational Site
    Roma, Italy
  • Pfizer Investigational Site
    Salerno, Italy
  • Pfizer Investigational Site
    San Donato Milanese, Italy
  • Pfizer Investigational Site
    Sassari, Italy
  • Pfizer Investigational Site
    Savona, Italy
  • Pfizer Investigational Site
    Siena, Italy
  • Pfizer Investigational Site
    Torino, Italy
  • Pfizer Investigational Site
    Venezia, Italy
  • Pfizer Investigational Site
    Hospitalet de Llobregat, Barcelona, Spain
  • Pfizer Investigational Site
    Girona, Cataluna, Spain
  • Pfizer Investigational Site
    Galdakao, Vizcaya, Spain
  • Pfizer Investigational Site
    Avila, Spain
  • Pfizer Investigational Site
    Barcelona, Spain
  • Pfizer Investigational Site
    Granada, Spain
  • Pfizer Investigational Site
    Huelva, Spain
  • Pfizer Investigational Site
    Jerez de La Frontera, Spain
  • Pfizer Investigational Site
    Madrid, Spain
  • Pfizer Investigational Site
    Marbella, Spain
  • Pfizer Investigational Site
    Sevilla, Spain
  • Pfizer Investigational Site
    Tarragona, Spain
  • Pfizer Investigational Site
    Valencia, Spain
  • Pfizer Investigational Site
    Newtonabbey, Belfast, United Kingdom
  • Pfizer Investigational Site
    Aylesbury, Buckinghamshire, United Kingdom
  • Pfizer Investigational Site
    ELY, Cambs, United Kingdom

Showing the first 100 of 121 sites across 5 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Gupta M, Martineau P, Tran T, Despres JP, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Blanco-Colio LM, Egido J, Langer A; ACTFAST investigators. Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. J Clin Pharmacol. 2012 Jun;52(6):850-8. doi: 10.1177/0091270011407196. Epub 2011 May 24. PubMed 21610204 ↗
  • Gensini GF, Gori AM, Dilaghi B, Rostagno C, Gaw A, Blanco-Colio LM, de Teresa E, Egido J, Farsang C, Leiter LA, Martineau P, Nozza A, Langer A; Achieve Cholesterol Targets Fast withAtorvastatin Stratified Titration Investigators. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Int J Cardiol. 2010 Jul 23;142(3):257-64. doi: 10.1016/j.ijcard.2008.12.213. Epub 2009 Feb 12. PubMed 19217176 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003, a primary completion of Feb 2004 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2007
First posted
Mar 2, 2007
Start
Jan 2003
Primary completionActual
Feb 2004
CompletionActual
Feb 2004
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00442845
Responsible party
Sponsor
First posted
Mar 2, 2007
Start date
Jan 2003
Primary completion
Feb 2004
Completion
Feb 2004
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion